arrow
N

Norma C. Gutiérrez

hematology department
H指数:65
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Study of post-translational modifications of p53 in multiple myeloma

多发性骨髓瘤中p53的翻译后修饰研究

2026-07-170
OA
Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study

NPM1突变急性髓系白血病强化治疗患者中变异等位基因频率的预后影响:PETHEMA研究

Blood
IF23.1
2026-06-100
OAAI
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

实验室间交叉验证由PCR检测到的急性髓系白血病融合基因和突变靶点:PETHEMA中心实验室的表现

2025-12-010
PRE
Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis

使用MATRix方案诱导治疗继发以塞替派为基础的巩固治疗的原发性中枢神经系统淋巴瘤的疗效:一项GELTAMO分析

2025-11-270
PRE
Clinic-biological features and prognostic significance of MGUS-like myeloma who underwent to autologous stem cell transplantation

临床生物学特征及自体干细胞移植后MGUS-like骨髓瘤患者的预后意义

2025-11-200
OAAI
European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma

欧洲骨髓瘤网络工作组关于下一代测序在 newly diagnosed multiple myeloma 预后分层中应用的共识声明

2025-10-130
OAAI
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

前瞻性真实世界评估t(11;14)在多发性骨髓瘤中的患病率及疾病生物学:MEDICI研究分析

2025-08-210
OAAI
Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation

探索cyclin D1在多发性骨髓瘤发病机制中的作用,超越细胞周期调控

2025-07-170
OAAI
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

高剂量白消安-美法仑 vs 美法仑及强化VRD方案用于新诊断多发性骨髓瘤:一项GEM III期试验

Blood
IF23.1
2025-06-140
PRE
Impact of the Addition of Daratumumab to the Frontline Treatment of Patients with Immunoglobulin Light-Chain Amyloidosis: A Single-Centre Experience

将达鲁单抗添加到免疫球蛋白轻链淀粉样变性患者一线治疗中的影响:一项单中心经验

CANCERS
IF4.4
2025-04-250
OA
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

新诊断多发性骨髓瘤早期复发的危险因素:细胞遗传学和初始治疗反应的影响

2025-04-240
OAAI
Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma

通过全外显子测序对弥漫性大B细胞淋巴瘤和浆细胞样淋巴瘤进行遗传亚型分型

2025-03-110
OA
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

t(11;14)是否总是一种标准风险细胞遗传学异常?GEM05MENOS65和GEM2012 PETHEMA/GEM移植试验的结果。

2025-01-250
PRE
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients

初诊多发性骨髓瘤患者Bcl-2家族蛋白表达谱分析

2024-12-130
OAAI
High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

多发性骨髓瘤的高风险细胞遗传学异常: petema-GEM经验

2024-12-100
OAAI
EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

EO2463肽免疫疗法在 newly diagnosed asymptomatic follicular lymphoma 患者中单药治疗产生客观临床应答,这些应答与抗肽特异性CD8记忆T细胞应答相关:EONHL1-20/Sidney研究

BLOOD
IF23.1
2024-11-050
PRE
Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Mosunetuzumab单药治疗在重度预治疗复发或难治性套细胞淋巴瘤患者中显示出令人鼓舞的疗效和可管理的安全性。

BLOOD
IF23.1
2024-11-051
PRE
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma
LEUKEMIA
IF13.4
2024-09-240
OAAI